Centogene and C-Path Strengthen Drug Development Alliance

Centogene NV (CNTG) has released an update.

Centogene N.V. and Critical Path Institute have signed a Memorandum of Understanding to enhance efforts in drug development for lysosomal diseases, aiming to expedite the creation of effective treatments and improve patient quality of life. The partnership leverages Centogene’s extensive biodata repository and genetic testing capabilities with C-Path’s expertise in collaborative drug development initiatives. This strategic alliance underscores both organizations’ commitment to transforming real-world data into life-saving therapies.

For further insights into CNTG stock, check out TipRanks’ Stock Analysis page.